Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) received a $50.00 target price from Cantor Fitzgerald in a research report issued on Tuesday, October 17th. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 136.41% from the stock’s previous close.
Several other brokerages also recently issued reports on PRTK. Zacks Investment Research downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. ValuEngine downgraded shares of Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday, September 18th. Raymond James Financial, Inc. reissued a “strong-buy” rating and issued a $36.00 price objective on shares of Paratek Pharmaceuticals in a research note on Thursday, August 24th. BidaskClub downgraded shares of Paratek Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, August 23rd. Finally, HC Wainwright raised their price objective on shares of Paratek Pharmaceuticals from $36.00 to $43.00 and gave the stock a “buy” rating in a research note on Tuesday, July 18th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $38.11.
Shares of Paratek Pharmaceuticals (NASDAQ PRTK) traded up 1.42% on Tuesday, reaching $21.45. The company’s stock had a trading volume of 186,659 shares. The firm’s 50 day moving average is $24.78 and its 200-day moving average is $22.91. The stock’s market cap is $595.47 million. Paratek Pharmaceuticals has a 52-week low of $9.80 and a 52-week high of $29.00.
Paratek Pharmaceuticals (NASDAQ:PRTK) last released its quarterly earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported ($0.64) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.89) by $0.25. The company had revenue of $7.51 million during the quarter, compared to analysts’ expectations of $7.50 million.
COPYRIGHT VIOLATION WARNING: This piece of content was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/10/27/paratek-pharmaceuticals-inc-prtk-given-a-50-00-price-target-by-cantor-fitzgerald-analysts.html.
Several institutional investors have recently bought and sold shares of PRTK. C WorldWide Group Holding A S raised its stake in shares of Paratek Pharmaceuticals by 449.3% during the second quarter. C WorldWide Group Holding A S now owns 439,400 shares of the specialty pharmaceutical company’s stock valued at $10,590,000 after acquiring an additional 359,400 shares in the last quarter. Pictet Asset Management Ltd. bought a new stake in shares of Paratek Pharmaceuticals during the second quarter valued at approximately $6,957,000. State Street Corp raised its stake in shares of Paratek Pharmaceuticals by 112.3% during the second quarter. State Street Corp now owns 616,112 shares of the specialty pharmaceutical company’s stock valued at $14,850,000 after acquiring an additional 325,856 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Paratek Pharmaceuticals by 275.9% during the first quarter. Renaissance Technologies LLC now owns 414,513 shares of the specialty pharmaceutical company’s stock valued at $7,979,000 after acquiring an additional 304,249 shares in the last quarter. Finally, Numeric Investors LLC bought a new position in Paratek Pharmaceuticals in the second quarter worth approximately $6,449,000. 80.52% of the stock is owned by hedge funds and other institutional investors.
About Paratek Pharmaceuticals
Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.
Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.